3 news items
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
RVNC
9 May 24
in product liability, intellectual property, class action or other lawsuits; our ability to limit or mitigate cybersecurity incidents; the volatility
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
RVNC
9 May 24
ourselves in product liability, intellectual property, class action or other lawsuits; our ability to limit or mitigate cybersecurity incidents
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
and our ability to defend ourselves in product liability, intellectual property, class action or other lawsuits; our ability to limit or mitigate
- Prev
- 1
- Next